idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
MHH haematologists successfully treat seriously ill patients with acquired haemophilia A with CAR-T cells.
Cell and gene therapies harbour great hopes for biomedicine. They are becoming increasingly important for diseases that are currently difficult or impossible to treat - for example, aggressive forms of cancer or rare diseases such as haemophilia, also known colloquially as haemophilia. At the Haemophilia Centre at the Clinic for Haematology, Haemostaseology, Oncology and Stem Cell Transplantation (Director Professor Dr Florian Heidel) at Hannover Medical School (MHH), a so-called CAR-T cell therapy has now been successfully carried out for the first time on a patient with acquired haemophilia A. The 39-year-old patient suffered from multiple haemophilia A symptoms. The 39-year-old suffered from severe haemorrhaging for several months and the individualised treatment attempt was his last hope. ‘The patient has a life-threatening autoimmune disorder, which means that his misdirected immune system has produced antibodies against his body's own coagulation factor,’ explains Professor Dr Andreas Tiede, Head of the Haemophilia Centre. Because all standard therapies failed, the doctors treating the patient used a procedure in which T cells belonging to the white blood cells were genetically modified so that they, as so-called CAR-T cells, switched off the falsely activated immune cells. The results have been published in the prestigious journal ‘Leukemia’.
Coagulation factor missing
Haemophilia A is either congenital, i.e. genetic, or the coagulation disorder is acquired, i.e. develops over the course of a lifetime. In the first case, those affected lack coagulation factor VIII, a protein produced in the liver. In the second case, the immune system mistakenly categorises the protein, which is vital for blood clotting, as foreign to the body, sends out immune cells against it and destroys it. In Germany, around 6,000 people are genetically affected by the disease and around 500 acquire it every year in the form of an autoimmune reaction. ‘In severe forms, patients suffer from spontaneous haemorrhages in the skin and muscles, as well as internal organs,’ explains Professor Tiede. People with congenital haemophilia also have a high risk of cerebral haemorrhages.
Misdirected immune system
The Haemophilia Centre at the MHH treats cases of both congenital and acquired haemophilia. If the coagulation factor is missing, those affected have to inject the proteins themselves several times a week - this is necessary on a regular basis due to the short half-life. However, the centre now also offers gene therapy in which the genetic information for the coagulation factor is transferred to the liver cells by means of a viral shuttle. As a small DNA ring in the cell nucleus, the gene produces the missing protein there. This very effective treatment is now covered by statutory health insurance.
The administration of these coagulation factors is often not effective in autoimmune diseases. Patients are usually given immunosuppressants, i.e. drugs that dampen the misdirected immune system. Another treatment option is the active ingredient emicizumab. The antibody is not a coagulation factor, but merely mimics its mode of action and activates blood coagulation. ‘However, none of the standard therapies worked for our patient, which is why we took a different approach,’ says PD Dr Christian Schultze-Florey. Together with his colleague Professor Dr Felicitas Thol, the haematologist treated the 39-year-old, who had a life-threatening illness, with CAR-T cell therapy. This method is primarily used in medicine to treat cancer. For this, the body's own T cells are taken from the blood. These are then genetically modified and equipped with a so-called chimeric antigen receptor (CAR). With the help of this receptor, the T cells can now recognise the target structures known as antigens on the cells against which they are to act.
CAR-T cell production directly on site
The genetically modified CAR-T cells are multiplied in the laboratory and then returned to the patient's body in a similar way to a blood transfusion. There they continue to multiply and - depending on the synthetic receptor - remain as a living weapon either against cancer cells or against misdirected defence cells. ‘In our case, the antigen receptor was directed against the CD19 protein on the surface of the CD19-B lymphocytes, which mistakenly produced antibodies against the coagulation factor,’ explains Professor Thol. What is special is that the CAR-T cells are produced directly at the MHH in the clean rooms of the Cellular Therapy Centre (CTC). The advantage: the cells are immediately available within a short time without having to be transported at great expense and independently of commercial companies.
No standard therapy yet
The therapy saved the 39-year-old's life. Just two months after the CAR T-cell transfusion, the coagulation factor recovered and the dangerous, uncontrolled bleeding stopped completely. ‘Although the treatment was very successful despite the poor initial conditions, this is an individual attempt at a cure,’ emphasises Professor Tiede. ‘Further studies are needed to be able to offer the effectiveness of CAR-T cell therapy for acquired haemophilia A as a standard therapy at some point.’
In order to be able to better evaluate and utilise the results of all treatment approaches in connection with CAR-T cell therapies, the Federal Joint Committee (G-BA), the highest decision-making body in the German healthcare system, would like to consolidate the data from the existing registers under the umbrella of a comprehensive cell and gene therapy register. Professor Tiede is also involved in setting up the national register.
Focus on cell and gene therapy at the MHH
The patient-oriented "point-of-care production" of CAR-T cells is currently only possible at a few centres and locations in Germany, making the MHH's focus on cell and gene therapy even more visible. Only through the close link between the Cellular Therapy Center (CTC), the CAR-T programme of the Department of Haematology and the focus on clinical cell therapy can advanced therapy medicinal products (ATMPs) be transferred directly from biomedical development to clinical cell therapy. As part of the newly founded Centre for Cell and Gene Therapy at the MHH, this offers new therapeutic options in the fields of immunology, nephrology and neurology, for example, through excellent collaboration between various clinics.
SERVICE:
The original paper ‘Anti-CD19 CAR-T cell therapy for acquired hemophilia A’ can be found here: https://www.nature.com/articles/s41375-025-02554-1
For further information, please contact Professor Dr Andreas Tiede, tiede.andreas@mh-hannover.de.
CAR-T cells (blue) use the synthetic receptor to recognise the target cell (yellow), bind to it and ...
Copyright: iStock.com, selvanegra
Criteria of this press release:
Journalists
Medicine
transregional, national
Research results, Scientific Publications
English
CAR-T cells (blue) use the synthetic receptor to recognise the target cell (yellow), bind to it and ...
Copyright: iStock.com, selvanegra
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
